07:34 AM EDT, 03/23/2026 (MT Newswires) -- Pfizer ( PFE ) and Valneva (VALN) said Monday that their investigational vaccine candidate LB6V against outdoor Lyme disease reduced the rate of confirmed cases by 73.2% compared with placebo in a phase 3 clinical study.

The efficacy result came 28 days after the fourth dose in the second season of the study, the companies said.

Meanwhile, an efficacy of 74.8% in preventing Lyme disease was observed a day after the fourth dose in the second season of the trial, the companies said.

"Fewer than anticipated" infections were accrued over the study period, and Pfizer ( PFE ) is planning further regulatory submissions for the vaccine candidate, the companies added.

LB6V is being jointly developed by Pfizer ( PFE ) and Valneva.